J Acupunct Res Search


J Acupunct Res > Volume 38(4); 2021 > Article
Jeon, Choi, Yoo, and Shin: Analysis of Clinical Research Trends for Acupotomy Treatment of Peripheral Facial Palsy


The purpose of this review was to investigate acupotomy treatment for peripheral facial palsy. By reviewing recent clinical trends, this may contribute to standardizing acupotomy treatment methods. There were 7 randomized controlled trials and 6 case series using acupotomy treatment for peripheral facial palsy published between January 01, 2014 and April 05, 2021, which were retrieved from 9 online databases. The number and characteristics of participants, main treatment sites, combination treatments, size of acupotomy needle, frequency and total period of treatment, evaluation indices, efficacy, and adverse events were analyzed. “Tender point or induration,” “infraorbical foramen,” and “buccal mucosa” were the most used treatment sites. The sizes of acupotomy needles varied from 20 mm to 80 mm in length, and 0.35 mm to 1.0 mm in diameter. One treatment cycle was performed every 3 to 57 days, and the number of treatments per treatment session ranged from 3 to 59 cycles. The results were evaluated using 1 to 4 evaluation indices and 9 different evaluation indices were used overall. The efficacy rate was the most used index, followed by the House-Brackmann grade, and electrocardiography. The “Risk of Bias 2,” categorized most studies as having “some concerns.” There were few adverse events reported.


Peripheral facial palsy is a cranial nerve condition/disease characterized by symptoms of paralysis or weakened facial muscles including a reduction in the affected-side forehead wrinkles, ptosis, dry eye or epiphora, and sagging corners of the mouth [1]. In the 2019 National Health Insurance Statistical Yearbook, 111,089 people with facial palsy visited Oriental medicine institutions, resulting in an annual expenditure of about 41.4 billion won [2]. In the National Health Insurance Review and Assessment Service in the 2020 list of frequent conditions/diseases statistics, facial nerve disorders and facial palsy specifically ranked 21st and 24th, respectively, in the total number of inpatients and outpatients at Oriental medical institutions. Oriental medicine treatment of facial nerve disorders and facial palsy have a large socio-economic impact [3].
In Oriental medicine, facial palsy has been treated by a variety of conservative treatments including acupuncture, pharmacoacupuncture, thread-embedding therapy, Pyung-Hyung acupuncture, Miso facial rejuvenation acupuncture, the scratching method, and Chuna therapy [49]. However, it has been reported that if the appropriate treatment was not given within 72 hours after acute onset of facial palsy, various sequelae may occur in about 30% of cases [10]. This requires appropriate studies for more effective therapies to minimize neurodegeneration [10].
Acupotomy is a type of acupuncture which was developed by combining Oriental acupuncture and Western medicine surgery. Due to its simpler manipulation, shorter treatment period, and less damage to the relevant tissues than the surgical treatment, studies have been focused upon its therapeutic effect in the musculoskeletal system such as the cervical and lumbar spine, and joints [11]. Studies where acupotomy has been applied to the treatment of facial palsy have been steadily published both nationally and internationally.
In this review, acupotomy treatment of peripheral facial palsy and the latest clinical research trends were assessed to examine the use and standardization of acupotomy treatment methods.

Materials and Methods

Study materials

Articles reporting acupotomy treatment of peripheral facial palsy which had been published from 2014 to April 05 2021 were reviewed. The initial design of this study was to review studies published in the last 10 years. However, in the 7 relevant articles published from 2010 to December 2013, 1 article did not have the full text available, 1 article was determined to be irrelevant after checking its title and abstract, and the remaining articles were all case series (CS) of < 20 cases. Randomized controlled trial (RCTs), non-RCTs, and CSs containing ≥ 20 were reviewed in this study, while in vivo or vitro studies, CSs containing < 20 cases, systematic reviews, and protocol articles were excluded. Facial palsy which occurred due to cerebrovascular conditions/diseases, injury, and tumor, or facial palsy which developed into bilateral symptoms were excluded from this review. Studies which reported using acupotomy singly or in combination with other treatments were selected.
This study was a retrospective study and so informed consent was not necessary.

Literature search

Online databases

The literature search was conducted until April 05, 2021 using 4 international databases [PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI)], and 5 national databases [Oriental medicine Advanced Searching Integrated System (OASIS), Science ON, DBPIA, Korean Studies Information Service System (KISS), and Research Information Sharing Service (RISS)].

Search words and terms

In international databases, the search words were English terms of “facial palsy,” “facial paralysis,” “Bell’s palsy,” “facial neuritis,” “acupotomy,” “needle knife,” “mini-scalpel,” and “stiletto needle.” Other similar words such as “facial paresis,” “Bell’s paralysis,” “acupotome,” and “acupotomology” were also used. In Chinese and Korean databases, in addition to the English terms, Chinese words and Korean words were also used. Search terms were surveyed both in the titles and the abstracts, and search terms and formulas were modified and combined to suit the characteristics of each database.

Data screening and extraction

Two independent researchers checked the titles and abstracts, and selected final articles by reviewing the full texts, after considering the predefined inclusion and exclusion criteria. Disagreements which could not be resolved were referred to a 3rd researcher to determine the suitability of an article.

Data analysis and management

The 2 researchers used EndNote X8 to retrieve information the title, author, publication year, study type, sample sizes, treatment sites, combined therapies, mean morbidity period, size of acupotomy needles, treatment cycle and frequency, evaluation indices, therapeutic effect, and adverse event reports.

Revised risk-of-bias tool for RCT

Two researchers assessed the risk of bias by applying the revised Cochrane Risk-of-Bias tool (RoB 2) to 7 RCT articles [12]. In response to each of relevant questions about bias, “ high risk of bias,” “some concerns” or “low risk of bias” were observed, and if there were any disagreements between the 2 researchers, a 3rd researcher was consulted to reach a final agreement.



A total of 58 articles were retrieved from international databases: PubMed (n = 0), Cochrane Library (n = 1), EMBASE (n = 2), and CNKI (n = 55). A total of 30 articles were retrieved from national databases: OASIS (n = 0), RISS (n = 1), Science ON (n = 1), DBPIA (n = 1), and KISS (n = 18). A total of 88 articles were reviewed. Amongst them, 23 articles were removed due to duplication. Forty articles were published prior to 2014 and those whose titles and abstracts were irrelevant to acupotomy for peripheral facial palsy were ruled out. After screening, 1 article, whose full text could not be found, and 3 CSs with < 20 cases were also excluded, which led to the final selection of 13 articles. The literature selection process was plotted in the form of a flow diagram of Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (Fig. 1).


Out of 13 articles, 12 articles were published in China, and 1 article was published in Korea. One article was published in 2014 and 2019. Two articles were published in 2015, 2016, 2018, and 2020. Three articles were published in 2017, indicating that the most articles were published in that year. In terms of the study type of the 13 articles, there were 7 RCTs and 6 CSs.

Analysis of selected articles

Sample size of study

In the selected 13 studies, an overall total of 655 participants were involved which consisted of 329 males and 326 females. Seven articles (2 RCTs and 5 CSs) had < 50 participants, 5 articles (5 RCTs) had > 50 < 100 participants, and 1 article (1 CS) had > 100 participants. Studies with the smallest, and largest number of participants were CSs which consisted of 23 and 128 participants, respectively (Tables 1 and 2).

Treatment sites and combination therapies

In performing acupotomy, 4 articles described their treatment points based on the anatomical structure site alone, 2 studies based it on the acupoint alone, and 2 studies based it on the facial or posterior cervical induration alone. Both the anatomical structure and the acupoint were used as the treatment points in 3 studies, and 1 study treated both acupoints and the induration. One article had no specific description of the treatment site in their article (Table 3).
In the intervention group, 3 studies applied only acupotomy, and 7 articles used a combination of acupotomy and other acupuncture therapies: 1 study used pharmacoacupuncture, 1 study used fire needling, and 5 studies used acupuncture.
Among the concurrent treatments in the intervention group in the studies reviewed, with the exception of acupuncture, there were 3 articles that described herbal medicine treatment and 5 articles which mentioned Western medicine treatment. Facial Scratching, physiotherapy, the cupping method, and Chuna therapy were mentioned in 1 article, each.

Mean morbidity period and intractable facial palsy

Of the 8 articles that reported the mean morbidity period clearly, 3 articles mentioned an average mean morbidity period of < 10 days, 1 article mentioned an average of ≥ 10 days < 3 months, 3 articles mentioned an average of > 3 months < 1 year, and 1 article mentioned an average of ≥ 1 year.
A total of the 5 articles mentioned intractable facial palsy was an inclusion criteria or the described symptoms similar to intractable facial palsy.

Size of acupotomy needles

Ten out of 13 articles specified the needle length and diameter, and the remaining article only mentioned the needle type and model number. Out of articles which reported the needle length and diameter, 2 studies used needles of 2 different sizes, depending on treatment points, in the same case (Table 4).

Treatment cycle and frequency

The treatment cycle was reported either 3 days, or 5–7 days, and the number of treatments for each treatment session was reported as 3 cycles, or 5–9 cycles in 10 articles which mentioned treatment cycle or session.
The total number of treatment cycles performed during the study period ranged from 2–10 cycles, and there were 3 articles with the total study period specified: 15 days, 3 weeks, and 30 days.

Evaluation index

All articles were assessed based on at least 1 index and at most 4 indices, and a total of 9 evaluation indices were used. The total efficacy rate, which was the most used, was applied 12 times, followed by the House-Brackmann grade, and electromyography which were used 4 times and 2 times, respectively. Each of the remaining 6 evaluation indices were used once.
When analyzing the number of evaluation indices used per study, 6 articles used 2 evaluation indices, and 5 articles used 1 evaluation index. One article used 3 evaluation indices, and 1 article used 4.

Therapeutic effect

In Lee’s study [13], 1 of the 7 articles where statistics was performed on the efficacy rate, the treatment group had a greater improvement in symptoms compared with the control group (based on the Yanagihara score), 1 week after the initial visit, and for the period 2 to 3 weeks following the initial visit, however, this difference was not statistically significant. In addition, postauricular pain intensity (measured by the Visual Analogue Scale score) did not significantly improve for the period 1 to 2 weeks following the initial visit, and when compared with the improvement to the control group, there was also no significant improvement 1 week after the initial visit, for the period 1 to 2 weeks following the initial visit, and 2 weeks after the first visit [13]. He et al [20] reported that in assessing the therapeutic effect, there was a significant improvement compared with the control group, based on the evaluation indices including the total efficacy rate, the Sunnybrook Facial Grade System, and the electromyography though the incidence of complications showed no significant improvement. The remaining therapeutic effects in the studies of Lee et al [13] and He et al [20] were all assessed to be significant, and the articles [1416,18,21,24] where statistical analysis was not performed had a total efficacy rate of between 94.4% and 100%.

Adverse events

Amongst the 13 articles, 8 articles did not mention safety, accidents, or adverse events, however, 4 articles specifically stated no safety concerns. Lee et al [13] only reported dizziness and poor conditions were sometimes observed which mostly disappeared within 3 days in sensitive patients, and there were no adverse events due to hematoma or nerve damage, and dropouts.

Assessment of the risk of bias

Seven of the 13 articles, which were RCT, were assessed for risk of bias in 5 assessment items using RoB 2. The results of assessing the risk of bias were plotted with Risk-of-Bias Visualization (ROBVIS) [26] (Figs. 2 and 3).

1. Bias arising from the randomization process

Only 1 article noted the allocation sequence, which was reported as random and concealed, so this article was categorized as a “low risk of bias.” The remaining 6 articles only briefly mentioned the randomization, so they were categorized as “some concerns” arising from the randomization process.

2. Bias due to deviations from the intended interventions

In 7 articles, bias was introduced into the study because deviations from the protocol had occurred in the blinding of the intervention from the participants and the researchers and a sham control was not implemented. Six of these articles, with no missing values, were categorized as “some concerns,” and 1 study which was conducted on half of the participants (after drop out) was categorized as “high risk of bias” due to a deviation from the intended patient number for intervention of the study.

3. Bias due to missing outcome data

Six articles described intervention results measured on all participants, and so these articles were categorized as “low risk of bias” due to missing data. The remaining article was categorized as “high risk of bias,” because the results were analyzed for half the participants (excluding the dropouts).

4. Bias in measurement of the outcome

In 6 articles, because the measurement of outcome was assessed by facial muscle functionality or the total efficacy rate, which is relatively objective, these studies were classified as “low risk of bias.” The remaining article was categorized as “some concerns” due to the use of the Visual Analogue Scale score, which is a subjective measurement of pain, that could affect the assessment of intervention outcome with patient knowledge of the intervention.

5. Bias in selection of the reported result

In 7 articles there was no mention of a separate protocol or prior plans, but they were categorized as “some concerns” of bias in selection of the reported result because there was no clear evidence of selectively reporting only specific intervention results or analyses estimating the results of specific interventions.


Facial nerve palsy is largely divided into supranuclear central palsy and infranuclear peripheral palsy, and 70% of facial palsy was reported to fall into peripheral facial palsy [27,28]. The facial nerve (the 7th cranial nerve), tends to be easily damaged because it has a longer pathway than any other cranial nerves, and passes through the narrow facial canal [29]. Inflammatory changes due to viral infection of the facial nerve can cause segmental demyelination and the resultant edema may apply pressure on the nerve within the facial canal causing facial nerve palsy [28].
Western medicine treatments for peripheral facial palsy include high-concentration oral steroids, and antiviral agents applied at the initial treatment, with painkillers concurrently administered when accompanied by neuralgia. When indicated, surgical treatments such as facial nerve decompression, and nerve transplantation are performed [30,31]. In particular, the nerve decompression has recently emerged as a solution for cases where > 90% of neurodegeneration occurs within 14 days from the onset [32].
The sites for acupotomy treatment in the intervention group were largely described in 3 ways: the anatomical structure, the acupoint, and the facial or posterior cervical induration. According to traditional acupoints and meridians, there are acupoints in the stomach, gallbladder, bladder, large intestine, and a triple energizer meridian which have been frequently used to treat facial palsy In addition, from an anatomical point of view, as the facial nerve receives blood from adjacent blood vessels such as the stylomastoid artery, persistent ischemia occurs due to inflammatory edema triggering neurodegeneration and causing facial dysfunction including facial palsy [33]. Acupoints like TE17, EX-HN16, ST07, SI18, ST04, TE23 and CV24 are influenced by the facial nerve, because they are located on the pathway of the facial nerve or in its vicinity [34]. It can be expected that acupotomy would not only provide the meridian-associated therapeutic effect through the relevant acupoints, but also create nerve decompression, and normalized blood supply to the relevant facial nerve. When treating buccal mucosa with acupotomy, similar effects as described above can be expected because it is also located on the pathway of the facial nerve. On the other hand, cervical vertebra spinous process, transverse process, and facet joints are the origins and insertions of several posterior cervical muscles, so acupotomy stimulation of those parts may remove facial nerve inflammation, edema, dehydration, and entrapment of adjacent blood vessels [35,36].
In 11 studies, the course of facial nerve palsy treatment was specified, varying from 10 days to > 1 year. Five articles mentioned intractable facial palsy in the participant inclusion criteria or described similar symptoms.
Ten articles stated length and diameter of acupotomy needles used in the treatment, and 2 studies used acupotomy needles of 2 different sizes, depending upon the treatment sites in the same study. Zhang et al [17] used a No. 4 needle measuring 50 mm × 0.6 mm and a No. 3 needle measuring 80 × 1.0 mm. It can be assumed that thicker and longer needles were used to ensure therapeutic facilitation with the same force to reach deeper structures such as the buccal mucosa. Lu reported a No. 4 needle which was 0.8 mm wide was inserted to the anterior and posterior borders of the styloid process, and a No. 4 needle which was 0.6 mm wide was inserted into the tender point, and the induration of the facial muscle, respectively. It can therefore be assumed that the tender point, and the induration on the face, are in a more superficial layer rather than the styloid process [25].
In He’s study, an acupotomy needle, and an acupuncture needle of the same size, 0.35 × 40 mm, were used in the treatment group and the control group, respectively. The control group received 1 treatment cycle daily, whereas 1 treatment cycle for the intervention treatment group was performed every 3 days. It can be assumed that more days were required for the treatment site recovery following acupotomy [20]. However, since only 3 articles specifically mentioned the total study period and the total number of treatment cycles, which varied from 2 cycles to 10 cycles, it was considered that studies in the future should design the total study period and the number of treatment cycles more specifically.
Among the 9 evaluation indices used in the 13 articles reviewed, the total efficacy rate was most frequently applied. It can be assumed that efficacy rate has the advantage of being a simpler, quicker assessment. However, it also has the disadvantage of possibly producing different values depending upon the assessor’s subjectivity in assessing facial functionality. Thus, evaluation indices should be itemized in more detail and more objective numerical values should be presented.
Regarding safety, accidents, or adverse events, only the study by Lee et al [13] reported dizziness and poor conditions were sometimes observed. However, as acupotomy is an invasive therapy that involves creating a stronger stimulation than achieved using acupuncture. Thus, concerns about infection, and damage to adjacent nerves and blood vessels, and imposing a physical burden, and an acupuncture-associated vasovagal response in sensitive patients, it is necessary to monitor the patient longer-term and on a more elaborate basis.
Bias indicates systematic errors created in the study, possibly overestimating or underestimating the study findings [37]. There were 7 RCT out of 13 articles assessed for risk of bias for 5 items. In assessing the bias arising from the randomization process, only 1 article was categorized as “low risk of bias,” suggesting that randomization of participants, especially the concealment of the allocation sequence should be designed more systematically. In blinding, only the study by He et al [20] inserted acupuncture needles to the control group which were the same size as the intervention group, while the remaining articles did not present any sham therapy. It was considered that it would be difficult to blind the participants and the intervention providers due to the shape of acupotomy needles and the invasive nature of acupotomy. As a result, 7 articles were categorized as “some concerns” in terms of the overall risk of bias.
It was reported that applying acupotomy to peripheral facial palsy improves facial expression muscle dysfunctions. However, all of 13 articles selected for this study were published in non-English speaking countries, and there may be more articles published in English or other languages which the search terms did not capture in the databases. This study also has the limitation that all 13 selected articles were not RCTs and therefore, a sufficient number of studies have not yet been published on acupotomy treatment of peripheral facial palsy. In addition, the risk of bias in many of the selected articles were not low risk, thus more systematic design of randomization and blinding is required.

Conflict of Interest

Conflicts of Interest

The authors have no conflicts of interest to declare.


Ethical Statement

This research did not involve any human or animal experiment.

Fig. 1
The flow diagram according to preferred reporting items for systematic reviews and meta-analyzes.
Fig. 2
Risk of bias graph.
Fig. 3
Risk of bias summary.
(X): High risk of bias, (+): Low risk of bias, (−): Some concerns.
Table 1
The Analysis of the Characteristics of Treatment.
First author (y) [reference] Study type
N (I:C)
Sample age (y) (I/C) Sample (M:F) (I/C) Course of condition/ disease (I/C) Acupoints (I) Size (L × D; mm) Treatment session & total period (I)
1. Lee (2014) [13] RCT
30 (15:15)
50.80 ± 4.18 / 54.07 ± 4.04 6:9 / 7:8 ≤ 10 D - MP+C7 SP: SCM, SC, TE17
- NL
- C2 SP+FJ
- C1 TP
- C1, C3 FJ
50 × 0.5 - Inpatient: 2 Tx/D
- Outpatient: 2-3 Tx/W (Total 3 W)
2. Zhao (2015) [14] CS
17–72 (Mean: 45.2) 16:9 2 H-3 D (Mean 1.5 D) - BC of affected side
- Meridian of newly paralyzed region
- -
3. Yang (2015) [15] CS
18–64 (39.16 ± 8.25) 8:15 5 D-10 Y (2.49 ± 0.79 Y) TP of cervical region - -
4. Tang (2016) [16] CS
15–73 18:24 3.04 ± 0.28 M ST07, TE17, ST02, EX-HN16, SI18, ST06, EX-HN4, GB14, ST04 (Choose 4-6 points) 40 × 0.5 (Type 1, No. 4) - 1 Tx /5-7 D
- 3 Tx /1 session (Min 2 Tx, Max 6 Tx)
5. Zhang (2016) [17] RCT
42 (21:21)
50.0 ± 5.6 / 52.0 ± 6.0 9:12 / 8:13 ≥ 2 M - MP
- Lower point of zygomatic arch
- Infraorbital foramen
- BC
50 × 0.6 (No. 4)
80 × 1.0 (No. 3)
- 1 Tx/4 D
- 4 Tx/1 session (Next Tx after 5 D)
6. Zhang (2017) [18] CS
Mean 37.6 17:8 3 D-6 M (Mean 4.32 M) TE17, GB04, ST02, CV24, EX-HN8, ST05, ST07, LI04
(+) LR03, BC against induration (3 points)
30 × 0.4 2nd Tx after 5 D of 1st Tx (Not exceed 3 Tx)
7. Zhang (2017) [19] RCT
52 (26:26)
45.21 ± 8.10 / 45.55 ± 8.46 16:10 / 15:11 ≥ 1–3 M ST07, TE17, ST02, EX-HN16, SI18, ST06, EX-HN4, GB14, ST04 (Choose 4–6 points) 40 × 0.5 (Type 1, No. 4) - 1 Tx/5-7 D
- 3 Tx /1 session
8. He (2017) [20] RCT
70 (35:35)
32.26 ± 9.47 / 31.55 ± 9.21 19:16 / 18:17 15–51 D (29.28 ± 6.34) / 16–54 D (28.77 ± 6.62) TD, nodule on 3 Yang meridians of hand and foot 40 × 0.35 1 Tx per 3 D (Total 10 Tx for 30 D)
9. Xu (2018) [21] CS
28–75 (38.1 ± 9.5) 72:56 - - - 2nd Tx after 5–7 D of 1st Tx (3–4 Tx)
10. Hong (2018) [22] RCT
60 (30:30)
25–47 (43.03 ± 5.27) / 28–65 (39.05 ± 6.43) 20:10 / 16:14 2.79 ± 1.30 D / 2.10 ± 0.85 D - 2.5 cm outer of midpoint of inferior nuchal line
- C2 SP
- Midpoint & outer 1/3 point of C2 SP-MP line
- C3–C6 SP
- 3–4 cm outer of C7 SP
- Medial border of subclavicular fossa
- BC (1 W after o/s)
20 × 0.35 - Tx at intervals of 3–5 D
- 5–9 Tx/1 session (+) BC: (1 Tx/W, 3 Tx/1 session)
11. Chen (2019) [23] RCT
62 (31:31)
21–68 (44.5 ± 23.5) / 21–67 (44.0 ± 23.0) 15:16 / 16:15 - STP 50 × 1.0 Next Tx after 1 W depending on progress
12. Wang (2020) [24] CS
23–61 (18.45 ± 6.48) 16:20 3 M-25 Y (5.5 ± 2.6 M) ① Face: EX-HN4, GB14, ST02, BL02, GB01, EX-HN8, CV24, ST04, BC
② Neck:
- C1–C7 TP & FJ
- C2 SP
- TP or induration on FJ, muscle
Type 1, No. 4 - 1 Tx/5–7 D
- 3 Tx/1 session
13. Lu (2020) [25] RCT 60 (30:30) 42.86 ± 13.62 / 42.42 ± 13.06 9:21 / 8:22 5.26 ± 3.18 D / 5.18 ± 3.22 D - STP (Ant. & post. margin)
- TP (Ant. & post. tubercle)+C2 SP
- Facial TP, induration
50 × 0.8 (No. 4)
50 × 0.6 (No. 4)
- 1 Tx/3 D
- 5 Tx/1 session (Total 15 D)

I, intervention group; C, control group; RCT, randomized controlled trial; CS, case series; MP, mastoid process; SP, spinous process; SCM, sternocleidomastoid muscle; SC, splenius capitis; NL, nuchal ligament; FJ, facet joint; TP, transverse process; STP, styloid process; TP, tender point; BC, buccal mucosa.

Table 2
Assessment and Main Results of the Studies.
First author (y) Intervention group Control group Evaluation index Main result (I/C) Adverse events
1. Lee (2014) [13] NKT+CA+PAtx+HM+WM CA+PAtx+HM+WM 1. Y-score
2. VAS
1. ① I) Significant improvement in all periods (P01, P12, P23, P02, P03) (p < 0.05)
C) Significant Improvement in all periods (p < 0.05) except P12 (p = 0.085)
② Comparison of improvement - P01, P23: I > C (p > 0.05), P12, P02, P03: I > C (p < 0.05)
2. ① Significant improvement in all periods (p < 0.05) except P12
(I: p = 0.116, C: p = 0.359)
② Comparison of improvement - P01, P12, P02: I > C (p > 0.05), P23, P03: I > C (p < 0.05)
Few cases of dizziness and poor condition (Recovered within 3 days)
2. Zhao (2015) [14] NKT+WNA+PT+ HM+WM - 1. H-B
2. ER
1. Gr. I: 17 cases, Gr. II: 6 cases, Gr. III: 2 cases, Gr. IV-VI: 0 cases
2. 100%
No occurrence
3. Yang (2015) [15] NKT+CA 1. ER 1. ① After 1st Tx: 95.65%
② After 2nd & 3rd Tx: 100%
Not mentioned
4. Tang (2016) [16] NKT+modified flash cupping method - H-B
1. Gr. I: 27 cases, Gr. II: 11 cases, Gr. III: 2 cases, Gr. IV-VI: 2 cases
2. 95.23%
No occurrence
5. Zhang (2016) [17] NKT FNA 1. ER 1. 100% / 66.7% (p < 0.05) Not mentioned
6. Zhang (2017) [18] NKT - 1. ER 1. 96% Not mentioned
7. Zhang (2017) [19] NKT+HOT+MNGF+WM MNGF+WM 1. H-B
2. ER
1. Gr. I: 0→8 / 0→3, Gr. II: 2→7 / 2→4, Gr. III: 7→7 / 6→3, Gr. IV: 7→2 / 7→5, Gr. V: 6→1 / 5→6, Gr. VI: 4→1 / 6→5 (p < 0.05)
2. 84.6% / 38.5% (p < 0.05)
No occurrence
8. He (2017) [20] NKT+WM CA+WM 1. ER
3. EMG
4. IC
1. 91.4% / 80.0% (p < 0.05)
2. 44.22 ± 10.45→76.64 ± 10.06 / 46.25 ± 10.32→68.18 ± 12.15 (p < 0.05)
3. ① CMAP pulse width:
0.85 ± 0.43 →1.24 ± 0.46 (p < 0.05) / 0.89 ± 0.47 →1.01 ± 0.35
② R1 latent period: 12.18 ± 1.98 →8.78 ± 1.85 (p < 0.05) / 12.61 ± 2.63→10.66 ± 2.27 (p < 0.05)
4. 11.43% / 20% (p > 0.05)
Not mentioned
9. Xu (2018) [21] NKT+CA+HM - 1. ER 1. 98.44% No occurrence
10. Hong (2018) [22] NKT+CA (CA: taiji six-he acupuncture) WM 1. ER 1. 96.67% / 83.33% (p < 0.05) Not mentioned
11. Chen (2019) [23] NKT+CA+WM+Chuna CA+WM+Chuna 1. ER
2. TCM
3. EMG
96.77% / 58.06% (p < 0.05)
2. ① Mouth & eye deviation: 0.45 ± 0.23 / 2.17 ± 0.44
② Facial numbness: 0.51 ± 0.25 / 2.20 ± 0.41
③ Eyelid insufficiency: 0.42 ± 0.27 / 2.22 ± 0.38
④ Facial convulsion: 0.52 ± 0.21 / 2.35 ± 0.40 (p < 0.05)
3. ① OO: 59.31 ± 11.56→98.54 ± 9.62 / 58.34 ± 12.94→75.88 ± 8.63
② FB: 18.39 ± 4.33→48.66 ± 4.93 / 19.27 ± 3.35→34.56 ± 3.87
③ LLS: 21.35 ± 7.22→82.51 ± 9.78 / 22.18 ± 7.57→55.37 ± 8.61 (p < 0.05)
Not mentioned
12. Wang (2020) [24] NKT+Facial scraping - 1. H-B
2. ER
1. 1.47 ± 0.73 → 4.56 ± 0.83
2. 94.4%
Not mentioned
13. Lu (2020) [25] NKT WM 1. FFAS
2. ER
1. 9.84 ± 4.68→27.16 ± 2.86 / 9.86 ± 4.66→23.68 ± 6.12 (p < 0.05)
2. 86.67% / 73.33% (p < 0.01)
Not mentioned

NKT, needle knife treatment; CA, common acupuncture; PAtx, pharmacoacupuncture; PT, physiotherapy; HM, herbal medicine; WM, western medicine; Y-score, Yanagihara score; VAS, visual analogue scale; Pαβ, period from the α th visit to β weeks later; WNA, warm needling acupuncture; H-B, House-Brackmann grade; ER, efficacy rate; Tx, treatment; FNA, fire needling acupuncture; HOT, hyperbaric oxygen therapy; MNGF, mouse nerve growth factor; TCM, TCM syndrome score; EMG, electromyography; SFGS, Sunnybrook facial grading scale; IC, the incidence of complications; OO, orbicularis oris; FB, frontal belly; LLS, Levator labii superioris; FFAS, facial nerve function assessment scale.

Table 3
The Frequency of Mentioning Acupotomy Treatment Sites.
Frequency Treatment points
5 Tender point or induration, Buccal mucosa of affected side,
ST02 (Infraorbical foramen)
4 GB14, ST07 (Lower point of zygomatic arch), C2 Spinous process
3 TE17, EX-HN4, ST04
2 EX-HN8, CV24, EX-HN16, ST06, SI18,
C1–3 Facet joint, Styloid process, Mastoid process
1 ST05, LI04, LR03, BL02, GB01, Anterior & posterior tubercle of transverse process of cervical spine, C1 Transverse process, C3–6 Spinous process, C4–C7 Facet joint, C7 Spinous process and its 3–4 cm outer point, Midpoint & outer 1/3 point of C2 spinous process-mastoid process line, Nuchal ligament, Medial edge of subclavian fossa
2.5 cm outer of midpoint of inferior nuchal line
Table 4
The Size of Acupotomy Needle and Frequency of use.
Size (mm)* Frequency
20 × 0.35 1
40 × 0.35 1
30 × 0.40 1
40 × 0.50 2
50 × 0.50 1
50 × 0.60 2
50 × 0.80 1
50 × 1.00 1
80 × 1.00 1

* Length × diameter.


1. Korean Acupuncture & Moxibustion Medicine Society Textbook Compilation Committee. The Acupuncture Medicine. Seoul (Korea): Hanmi Medical Publishing Company. 2016:656–660. [in Korean].

2. Kim SM, Kim YI. 2019 National Health Insurance Statistical Yearbook. Health Insurance Review & Assessment Service, National Health Insurance Service. 2020:656, [in Korean].

3. Healthcare Bigdata Hub Frequent disease statistics of inpatients in 2020 [Internet]. [cited 2021 Jun 01]. Available from: http://opendata.hira.or.kr/op/opc/olapHifrqSickInfo.do. [in Korean].

4. Lee JH, Yang TJ, Kim SW, Jeong JY, Ma YH, Oh JS, et al. Efficacy between Hwangryunhaedok-tang Pharmacopuncture Therapy and Hominis Placenta Pharmacopuncture Therapy on Peripheral Facial Paralysis: Retrospective Comparison Study. Korean J Acupunct. 2015;32:199–207. [in Korean].
5. Lee YJ, Choi YA, Kim TJ, Roh JD. Effectiveness of Thread-embedding Therapy Combined with Korean Medicine Treatment on Acute phase of Bell’s Palsy. J Korean Med Ophthalmol Otolaryngol Dermatol. 2021;34:1–12. [in Korean].

6. Yoo JH, Kim KW, Kim DH, Kim JH, Kim HH, Chung IT, et al. A Controlled Trial on the Effect of Complex Oriental Medical Treatment with or without Pyung-Hyung Acupuncture on the Treatment of Peripheral Facial Palsy. J Korean Acupunct Moxibution Soc. 2012;29:121–128. [in Korean].

7. Lee SY, Ko JM, Kim JH, Kwon HJ, Chung JY, Song JH, et al. Case Study of Miso Facial Rejuvenation Acupuncture on Intractable Facial Palsy. J Korean Acupunct Moxib Soc. 2009;26:163–171. [in Korean].

8. Oh MJ, Song HS. Effect of Scratching Method Complex Therapy on the Patients with Peripheral Facial Paralysis. J Korean Acupunct Moxibution Soc. 2011;28:1–7. [in Korean].

9. Jeong JY, Lee ES, Seo DG, Shin SY, Kim SY, Kwon HK, et al. The Clinical Research of Cervical Chuna Treatment’s Effects on Bell’s Palsy. Acupunct. 2014;31:45–55. [in Korean].

10. Han DG, Kang AH, Sung JY, Oh JH, Lee YR, Lee HC, et al. A Case Report of Facial Nerve Palsy Treated with Korean Medicine Treatment. J Int Korean Med. 2018;39:277–285. [in Korean].
11. Yuk DI, Kim KM, Jeon JH, Kim YI, Kim JH. A Review of Trends for Acupotomy. Acupunct. 2014;31:35–43. [in Korean].
12. Higgins JPTAD, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. Edited by Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. In: Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration. 2021:

13. Lee ES, Jeong JY, Seo DG, Shin SY, Seo JC, Seo YJ, et al. Clinical Research of Cervical Acupotomy Effects with Acupuncture on Facial & Trigeminal Nerve Branch on Peripheral Facial Paralysis and Postauricular Pain. Acupunct. 2014;31:143–154. [in Korean].
14. Zhao LW. Acupotomy combined with warm needling and physiotherapy to treat idiopathic facial palsy. Chin J Convalescent Med. 2015;24:704–706. [in Chinese].

15. Yang JG, Cai ZB, Sun XF. 23 Cases of Peripheral Facial Paralysis with Cervical Symptoms Treated By Acupotomy. Chin Med Cosmetol. 2015;5:116–118. [in Chinese].

16. Tang F, Liu YB, Lu WB, Jiang XP. 42 Cases of Intractable Facial Paralysis Treated with Small Needle-knife and Modified Flash Cupping Method. J Extern Ther Tradit Chin Med. 2016;25:30–31. [in Chinese].

17. Zhang J, Gong XQ, Wang ZM, Li DQ, He F, Zhang XM, et al. Observation on Therapeutic Effect of Small Needle-knife on Intractable Facial Paralysis. Inner Mongolia J Tradit Chin Med. 2016;35:120–121. [in Chinese].

18. Zhang LG. Observation on Needle-knife Treatment in 25 Cases of Facial Paralysis. Health Way. 2017;16:296, [in Chinese].

19. Zhang HY. Effect of small needle-knife cooperated with hyperbaric oxygen and neurotrophic drugs in the treatment of intractable facial paralysis. China Med Herald. 2017;14:163–166. [in Chinese].

20. He CH, Liang WL. Clinical Observation of Blade-needle for Convalescence of Facial Neuritis and Its Influence on EMG. J Clin Acupunct Moxibustion. 2017;33:35–38. [in Chinese].

21. Xu SQ. Clinical Observation on Treatment of 128 Cases of Facial Paralysis with Daqinjiao- Decoction and Qianzheng Powder Combined with Acupuncture, Acupoint-Embedding, and Small Needle-knife. J Clin Med Literature. 2018;5:83–96. [in Chinese].

22. Hong XT, Xuan BJ. Treatment of 30 Cases of Facial Neuritis with Taiji Six-he Acupuncture Combined with Blade-needle. J Extern Ther Tradit Chin Med. 2018;27:35–36. [in Chinese].

23. Chen S, Li XH, Jiang RH, Li L. Efficacy of “Zhendao Songjie Jingtu” on peripheral facial neuritis. Clin J Chin Med. 2019;11:40–43. [in Chinese].

24. Wang LZ. 36 Cases of Intractable Facial Paralysis treated with acupotomy therapy combined with facial scraping. China Naturopathy. 2020;28:38–40. [in Chinese].

25. Lu SC, Chen CH, Yuan SM. Treatment of 30 Cases of Acute Facial Neuritis with Needle-knife. Jiangxi J Tradit Chin Med. 2020;51:55–57. [in Chinese].

26. McGuinness LA, Higgins JPT. Risk-of-bias Visualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61.
crossref pmid
27. Hong KE. Prevalence and Treatment Pattern of Korean Patients with Facial Palsy. J Korean Acupunct Moxibution Soc. 2010;27:137–146. [in Korean].

28. Bae HB, Yoon HJ, Ko WS, Park SH, Keum DH. A Retrospective Study of Facial Paralysis Sequelae for Korean Medical Treatment. J Korean Med Ophthalmol Otolaryngol Dermatol. 2019;32:59–73. [in Korean].

29. Lim BS, Hwang KG, Shim KS. Temporary Facial Nerve Paralysis after Post-op Edema-A Case Report-. J Dent Anesth Pain Med. 2005;5:112–116. [in Korean].
30. Yoo HJ, Kim GJ. Analysis of Pharmacopuncture Used in Facial Nerve Palsy Articles that Published in the Journal of Korean Medicine. J Korean Med Ophthalmol Otolaryngol Dermatol. 2019;32:105–115. [in Korean].

31. Jo YK, Lee YJ, Kim ES, Jeon JH, Kim YI. Review on Clinical Studies of Facial Palsy Sequelae Treatment. J Haehwa Med. 2019;28:1–12. [in Korean].

32. Lee SY, Jeon S, Kim YH. Clinical Implication of Facial Nerve Decompression in Complete Bell’s Palsy: A Systematic Review and Meta-Analysis. Clin Exp Otorhinolaryngol. 2019;12:348–359. [in Korean].
crossref pmid pmc
33. Korean Acupuncture & Moxibustion Medicine Society Textbook Compilation Committee. The Acupuncture Medicine. Seoul (Korea): Hanmi Medical Publishing Company. 2016:174–175, 180.

34. Wu BH, Chen Y, Dong WG. Superficial needling for treatment of dysfunction of facial nerves and the relation with anatomy. Chin Acupunct Moxibustion. 2004;24:585–587. [in Chinese].

35. Lee SE, Yoon HJ, Ko WS. Research Trends on Non-surgical Treatment of Peripheral Facial Paralysis Sequelae. J Korean Med Ophthalmol Otolaryngol Dermatol. 2018;31:42–64. [in Korean].

36. Gong HM, Jun SA, Chung YJ, Kim JR, Lee JH, Lee HJ, et al. Efficacy and Safety of Mini-scalpel Acupuncture, Non-Steroidal Anti-Inflammatory Drugs or Combined Treatment for Chronic Neck Pain: An Assessor-Blinded Randomized Controlled Pilot Study. Korean J Acupunct. 2020;37:14–23. [in Korean].
37. Kim SY, Park DA, Seo HJ, Shin SS, Lee SJ, Lee M et al. Health Technology Assessment Methodology: Systematic Review. National Evidence-based Healthcare Collaborating Agency. Seoul (Korea): 2020:80–96. [in Korean].

Article and Issues
For this Journal
For Authors
Submit Manuscript
Editorial Office
Gil Korean Medical Hospital, Gachon University
Keunumul-Ro, Chung-Ku, Inchoen 22138, Korea
Tel: +82-70-7606-6353,4    Fax: +82-32-232-3334    E-mail: jared@e-jar.org                

Copyright © 2021 by Korean Acupuncture & Moxibustion Medicine Society.

Developed in M2PI

Close layer
prev next